Larry Horn

TNG Pharmaceuticals, Inc. engages in the development of a vaccine that reduces the horn fly population. Its vaccine counteracts the horn fly's anti-clotting agent, Thrombostasin, by triggering an immune response that clots the blood at the point of the wound. The company was founded by Larry Horn and Jennifer Corbin in 2011 and is headquartered in Louisville, KY.

TNG Pharmaceuticals, Inc. engages in the development of a vaccine that reduces the horn fly population. Its vaccine counteracts the horn fly's anti-clotting agent, Thrombostasin, by triggering an immune response that clots the blood at the point of the wound. The company was founded by Larry Horn and Jennifer Corbin in 2011 and is headquartered in Louisville, KY.

TNG Pharmaceuticals, Inc. engages in the development of a vaccine that reduces the horn fly population. Its vaccine counteracts the horn fly's anti-clotting agent, Thrombostasin, by triggering an immune response that clots the blood at the point of the wound. The company was founded by Larry Horn and Jennifer Corbin in 2011 and is headquartered in Louisville, KY.

TNG Pharmaceuticals, Inc. engages in the development of a vaccine that reduces the horn fly population. Its vaccine counteracts the horn fly's anti-clotting agent, Thrombostasin, by triggering an immune response that clots the blood at the point of the wound. The company was founded by Larry Horn and Jennifer Corbin in 2011 and is headquartered in Louisville, KY.

TNG Pharmaceuticals, Inc. engages in the development of a vaccine that reduces the horn fly population. Its vaccine counteracts the horn fly's anti-clotting agent, Thrombostasin, by triggering an immune response that clots the blood at the point of the wound. The company was founded by Larry Horn and Jennifer Corbin in 2011 and is headquartered in Louisville, KY.